DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,529,000 | +322.1% | 115,000 | +342.3% | 0.69% | +214.7% |
| Q1 2022 | $836,000 | -81.3% | 26,000 | -74.0% | 0.22% | -82.3% |
| Q4 2021 | $4,460,000 | +17.9% | 100,000 | +33.3% | 1.23% | +13.4% |
| Q3 2021 | $3,784,000 | -40.4% | 75,000 | -7.4% | 1.09% | -37.8% |
| Q2 2021 | $6,354,000 | +14.7% | 81,000 | -16.5% | 1.75% | +10.5% |
| Q1 2021 | $5,539,000 | +15.0% | 97,000 | +68.7% | 1.58% | +10.5% |
| Q4 2020 | $4,816,000 | -18.5% | 57,500 | -65.2% | 1.43% | -20.8% |
| Q3 2020 | $5,912,000 | +88.1% | 165,000 | +26.9% | 1.81% | +92.1% |
| Q2 2020 | $3,143,000 | +99.4% | 130,000 | +44.4% | 0.94% | +35.6% |
| Q1 2020 | $1,576,000 | – | 90,000 | – | 0.69% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |